Physician profile
Robert C Maynor
NPI 1497704175
$1,372.11
in general payments reported to CMS, 2019-2025
16 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.25 · 2021: $158 · 2022: $287 · 2023: $320 · 2024: $300 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $339.96 | 2021-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Alexion Pharmaceuticals, INC. | $183.37 | 2023-2024 | Ultomiris |
| Abbvie INC. | $177.57 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $119.86 | 2021-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $98.53 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $94.76 | 2024-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $72.52 | 2020-2021 | |
| Allergan, INC. | $55.46 | 2020-2021 | |
| Ocular Therapeutix, INC. | $43.62 | 2022-2024 | Dextenza |
| Rxsight INC | $42.40 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $35.80 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $33.22 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Kala Pharmaceuticals, INC. | $24.56 | 2021 | |
| Sight Sciences, INC. | $18.65 | 2024 | Omni Surgical System |
| Oyster Point Pharma, INC. | $16.75 | 2023 | Tyrvaya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $15.08 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maynor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.